Brief: Oramed Initiates Second Phase 3 Oral Insulin Study Under FDA's Approved Dual Concurrent Protocol

Oramed Pharmaceuticals

23/03/2021 13:01

March 23 (Reuters) - Oramed Pharmaceuticals Inc  ORMP.O :
    * ORAMED INITIATES SECOND PHASE 3 ORAL INSULIN STUDY UNDER
THE
FDA'S APPROVED DUAL CONCURRENT PROTOCOL
    * ORAMED PHARMACEUTICALS INC - PATIENTS SCREENED IN
ORA-D-013-2
STUDY WHICH IS RECRUITING 450 PATIENTS IN 53 SITES IN U.S.,
EUROPE AND ISRAEL

Source text for Eikon:  ID:nPn4D4K5la 
Further company coverage:  ORMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))